ARGX-213 tested in healthy volunteers for safety
NCT ID NCT06968338
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed phase 1 trial tested the safety of ARGX-213 in 88 healthy adults aged 18 to 65. Participants received either the drug or a placebo, and researchers monitored side effects, drug levels in the blood, and immune responses over up to 21 weeks. The study aims to understand how ARGX-213 behaves in the body before any future disease-focused trials.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ARGX-213
- What could go wrong
- This is an early phase 1 study in healthy volunteers, so it does not test any disease treatment. The results only show safety and how the drug moves in the body, not whether it works for any condition.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Altasciences
Montreal, QC H3P 3P1, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug pass its first safety hurdle?
- Can a new drug play nice with common medicines? a trial investigates
- Could a new pill quiet chronic pain? early trial puts it to the test
- Brain waves under pressure: can light uncover the signature of mental work?
- Can acting as patients teach nurses to truly listen?
- Who decides for you? survey asks incarcerated older adults